GEN Exclusives

More »

GEN News Highlights

More »
Apr 8, 2008

NextGen Acquires Pending Patent from Oxon Life Science Linked to Breast Cancer Stem Cells

  • NextGen Bioscience has obtained use, commercialization, and ownership rights of Oxon Life Science’s patent application related to cancer stem cells.

    The application describes an improved method of identifying and purifying undifferentiated stem cells from solid breast carcinomas that are usually resistant to conventional therapies, the companies explain.

    “Based on evidence that cancers such as breast cancer and prostate cancer proliferate primarily from cancer stem cells, this technology will be vital for both early diagnosis and identifying targets for a new generation of targeted therapeutic strategies,” notes NextGen CEO, Konstantinos Kardiasmenos.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?